Loading
Monte Rosa Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Leo Chandra P., was filed 25 Mar 2025.
Insider Decl.
149
Thresholds
n/a
Buy Volume
€29M
4 ops. · all time
Sell Volume
€14M
39 ops. · all time
Who traded when
BuySaleMarkus Warmuth7 sales
Dunn Edmund5 sales
Filip Janku5 sales
Jennifer Champoux5 sales
Sharon Townson4 sales
Nickson Philip2 sales
+3 other insiders
Since the insiders bought
- +185.4%Entry US$5.49 · Close at T+365 US$15.67
- -54.5%Entry US$22.24 · Close at T+365 US$10.11
- -54.5%Entry US$22.24 · Close at T+365 US$10.11
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Monte Rosa Therapeutics, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$26.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,911 of 26,248 companies
15.7
score / 100
Value25
Quality7
FCF yld-2.9%
Earn yld-4.0%
EV/EBITDA·
ROE-43%
Gross mgn·
Net mgn-31%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.22
Analyst consensus
8 analystsStrong buy
US$19.00Target US$26.88(+140%)US$37.00
Income statement
RevenueUS$123.7M
EBITDA-US$45.9M-37% margin
Net income-US$38.6M-31.2% margin
Valuation
PER (forward)-6.1x
P/Book2.0x
Beta1.37
Balance sheet & cash
Market capUS$957.2M
Total debtUS$39.2M
Free Cash Flow-US$27.5M
Debt / Equity8%
Profitability & ownership
ROE-42.7%
ROA-21.6%
% insiders0.6%
% institutions116.5%
Last declaration on 6 October 2026
Declarations149 total
13 shares@ US$10.560.0000% mcap100.0% of flowCommon StockSEC:0001193125-26-415540:0
9,500 shares@ US$23.18090.022% mcap34.5% of flowCommon StockSEC:0001193125-26-307791:0
4,351 shares@ US$3.980.0017% mcap5.8% of flowCommon StockSEC:0001193125-26-306110:0
9,500 shares@ US$23.18090.022% mcap100.0% of flowCommonSEC144:0001950047-26-007144
4,351 shares@ US$23.38080.010% mcap34.1% of flowCommonSEC144:0001969223-26-000786
5,600 shares@ US$23.24950.013% mcap73.7% of flowCommon StockSEC:0001193125-26-297558:1
400 shares@ US$24.130.0010% mcap5.5% of flowCommon StockSEC:0001193125-26-297558:2
6,000 shares@ US$6.140.0037% mcap20.9% of flowCommon StockSEC:0001193125-26-297558:0
1,000,000 shares0Common StockSEC:0001193125-26-296490:0
15,000 shares0Common StockSEC:0001193125-26-296490:2
15,000 shares0Common StockSEC:0001193125-26-296490:1
5,407 shares@ US$23.900.013% mcap100.0% of flowCommonSEC144:0001950047-26-006665
10,000 shares@ US$23.11100.0% of flowCommon StockSEC:0001193125-26-290484:1
10,000 sharesCommon StockSEC:0001193125-26-290484:0
6,000 shares@ US$22.9511.5% of flowCommon StockSEC:0001193125-26-290486:1
6,000 sharesCommon StockSEC:0001193125-26-290486:0
6,000 shares@ US$22.290.013% mcap13.6% of flowCommonSEC144:0001950047-26-006612
10,000 shares@ US$23.110.023% mcap100.0% of flowCommonSEC144:0001950047-26-006574
3,000 shares@ US$20.0025.4% of flowCommon StockSEC:0001193125-26-282736:1
2,175 shares@ US$20.0011.4% of flowCommon StockSEC:0001193125-26-282735:1
30,000 shares@ US$21.422754.0% of flowCommon StockSEC:0001193125-26-282740:3
2,175 sharesCommon StockSEC:0001193125-26-282735:0
6,000 sharesCommon StockSEC:0001193125-26-282740:0
11,845 shares@ US$20.221420.1% of flowCommon StockSEC:0001193125-26-282740:1
30,000 sharesCommon StockSEC:0001193125-26-282740:2
25 of 149 declarations
About Monte Rosa Therapeutics, Inc.
On June 28, 2021, 16 filers bought at Monte Rosa Therapeutics, Inc. for EUR 231,999,527 in total: New Enterprise Associates 17, L.P., Joshua Makower and Carmen Chang, all 10% Owners, each reported EUR 16,724,085. The 17 purchases in the record amount to EUR 232,053,407, and 16 buy filings are flagged as clustered. They are 30% of open-market trades.
Sales are more numerous, 39, but far smaller: EUR 13,978,699 in total, with a median of EUR 52,726. The three largest are by Versant Venture Capital VI, L.P.: EUR 6,625,362 on September 20, 2024, EUR 2,952,873 on September 11, 2024 and EUR 805,108 on October 28, 2024. The same filer, a 10% Owner, is the most active, with 20 filings, one purchase and 7 sales. Jennifer Champoux, Chief Operating Officer, has 12.
Read moreShow less
The record gathers 149 filings from 31 filers between June 28, 2021 and October 5, 2026: 60 in 2021, 19 in 2024, 8 in 2025 and 62 in 2026. All 17 purchases have a stored 90-day result, with a median of 1.8% (stored results, not a forecast). Last twelve months: 62 filings, 29 sales, no purchase.
